Alto Neuroscience raises $60M (equity + credit) to help fix the “trial and error” approach to psychiatric medication

By SharpBrains | January 31, 2023

Alto Neu­ro­science bags $25M for four Phase II drugs (End­points News): Anoth­er $25 mil­lion is flow­ing the way of a Cal­i­for­nia biotech attempt­ing to fix the “tri­al and error” sys­tem in neu­ro­science drug R&D. Alto Neu­ro­science picked up the cap­i­tal from Alpha Wave Ven­tures via an exten­sion to its Series B, bring­ing total equi­ty raised…

Read More

Click Therapeutics raises $30 million in debt to advance commercialization of smoking cessation app Clickotine

By SharpBrains | December 4, 2020

Click Ther­a­peu­tics Secures $30M in Growth Cap­i­tal from K2 HealthVen­tures to Expand Oper­a­tions (press release): Click Ther­a­peu­tics, Inc. (“Click”), a leader in Dig­i­tal Ther­a­peu­tics™ solu­tions as pre­scrip­tion med­ical treat­ments, today announced $30 mil­lion in debt financ­ing from K2 HealthVen­tures (K2HV), a health­­care-focused spe­cial­ty finance com­pa­ny, to accel­er­ate com­mer­cial­iza­tion of its lead­ing smok­ing ces­sa­tion solu­tion, Clickotine™,…

Read More